Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Base Genomics logo is in the top left-hand corner. Below it is a table with a calculator, a clipboard with papers attached and stacks of silver coins descending in height from left to right.

Epigenetics company Base Genomics has launched with a team of leading scientists and clinicians to set a new gold standard in DNA methylation detection.

The company has closed an oversubscribed seed funding round of $11 million USD (£9 million GBP) to progress the development of its TAPS technology, initially focusing on developing a blood test for early-stage cancer and minimal residual disease. The funding round was led by Oxford Sciences Innovation and also included investors with industry expertise in genomics and oncology.

Base Genomics is led by a highly experienced team of scientists and clinicians, including Dr Vincent Smith, a world-leader in genomic product development and former Illumina VP; Dr Anna Schuh, Head of Molecular Diagnostics at the University of Oxford and Principal Investigator on over 30 clinical trials; Drs Chunxiao Song and Yibin Liu, co-inventors of TAPS at the Ludwig Institute for Cancer Research, Oxford; and Oliver Waterhouse, previously an Entrepreneur in Residence at Oxford Sciences Innovation and founding team member at Zinc VC.

Read the full story here.